BetterLife Pharma (BETRF) has completed their recently announced public offering with gross proceeds amounting to US $100 million dollars. The offering was a success, as some key investors have participated with notable names being Deep Track Capital, RA Capital and Perceptive Advisors. This should fund the company through phase 1 and phase 2 clinical development of BETR-001 for cluster headache, with the timing to be determined. After paying the brokers their 7% fee, the company's financial snapshot should look similar to this.
Financial Statistics:
- 93M dollars cash
- 720 million shares outstanding
- 194 million market cap
- 93M dollars cash
- 720 million shares outstanding
- 194 million market cap
Chart of BETRF below.
